121 related articles for article (PubMed ID: 15572423)
1. Human bladder as a novel target for vitamin D receptor ligands.
Crescioli C; Morelli A; Adorini L; Ferruzzi P; Luconi M; Vannelli GB; Marini M; Gelmini S; Fibbi B; Donati S; Villari D; Forti G; Colli E; Andersson KE; Maggi M
J Clin Endocrinol Metab; 2005 Feb; 90(2):962-72. PubMed ID: 15572423
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog.
Crescioli C; Ferruzzi P; Caporali A; Mancina R; Comerci A; Muratori M; Scaltriti M; Vannelli GB; Smiroldo S; Mariani R; Villari D; Bettuzzi S; Serio M; Adorini L; Maggi M
Endocrinology; 2003 Jul; 144(7):3046-57. PubMed ID: 12810561
[TBL] [Abstract][Full Text] [Related]
3. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
Morelli A; Vignozzi L; Filippi S; Vannelli GB; Ambrosini S; Mancina R; Crescioli C; Donati S; Fibbi B; Colli E; Adorini L; Maggi M
Prostate; 2007 Feb; 67(3):234-47. PubMed ID: 17163492
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
Adorini L; Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Fibbi B; Morelli A; Uskokovic M; Colli E; Maggi M
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):689-93. PubMed ID: 17241782
[TBL] [Abstract][Full Text] [Related]
6. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia.
Crescioli C; Maggie M; Vannelli GB; Luconi M; Salerno R; Barni T; Gulisano M; Forti G; Serio M
J Clin Endocrinol Metab; 2000 Jul; 85(7):2576-83. PubMed ID: 10902811
[TBL] [Abstract][Full Text] [Related]
7. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.
Comeglio P; Chavalmane AK; Fibbi B; Filippi S; Marchetta M; Marini M; Morelli A; Penna G; Vignozzi L; Vannelli GB; Adorini L; Maggi M
J Endocrinol Invest; 2010 Nov; 33(10):730-8. PubMed ID: 20386089
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.
Crescioli C; Ferruzzi P; Caporali A; Scaltriti M; Bettuzzi S; Mancina R; Gelmini S; Serio M; Villari D; Vannelli GB; Colli E; Adorini L; Maggi M
Eur J Endocrinol; 2004 Apr; 150(4):591-603. PubMed ID: 15080791
[TBL] [Abstract][Full Text] [Related]
9. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.
Marchiani S; Bonaccorsi L; Ferruzzi P; Crescioli C; Muratori M; Adorini L; Forti G; Maggi M; Baldi E
J Cancer Res Clin Oncol; 2006 Jun; 132(6):408-16. PubMed ID: 16485114
[TBL] [Abstract][Full Text] [Related]
10. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
11. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility.
Tiwari A
IDrugs; 2009 Jun; 12(6):381-93. PubMed ID: 19517319
[TBL] [Abstract][Full Text] [Related]
12. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
Adorini L; Penna G; Fibbi B; Maggi M
Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021
[TBL] [Abstract][Full Text] [Related]
14. Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction.
Schröder A; Colli E; Maggi M; Andersson KE
BJU Int; 2006 Sep; 98(3):637-42. PubMed ID: 16925765
[TBL] [Abstract][Full Text] [Related]
15. Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells.
Huang YW; Wang LS; Chang HL; Ye W; Shu S; Sugimoto Y; Lin YC
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):24-33. PubMed ID: 16854582
[TBL] [Abstract][Full Text] [Related]
16. Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells.
Sagrinati C; Sottili M; Mazzinghi B; Borgogni E; Adorini L; Serio M; Romagnani P; Crescioli C
Transpl Int; 2010 Sep; 23(9):914-23. PubMed ID: 20302596
[TBL] [Abstract][Full Text] [Related]
17. Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue.
Crescioli C; Villari D; Forti G; Ferruzzi P; Petrone L; Vannelli GB; Adorini L; Salerno R; Serio M; Maggi M
Mol Cell Endocrinol; 2002 Dec; 198(1-2):69-75. PubMed ID: 12573816
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells.
Crescioli C; Maggi M; Luconi M; Vannelli GB; Salerno R; Sinisi AA; Bonaccorsi L; Ferruzzi P; Barni T; Forti G; Serio M
Prostate; 2002 Jan; 50(1):15-26. PubMed ID: 11757032
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
